Using Bevacizumab to Treat Retinopathy of Prematurity
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
This study is testing if a new eye treatment called bevacizumab can help prevent vision loss in premature infants with severe retinopathy of prematurity when other treatments aren't an option.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 1 Month to 12 Months |
| Sex | All |
| Sponsor | Asociación para Evitar la Ceguera en México Academic / other |
| Drugs / interventions | bevacizumab |
| Locations | 1 site (Mexico City, Mexico DF) |
| Trial ID | NCT00346814 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and effectiveness of intravitreal bevacizumab, an antiangiogenic therapy, for treating retinopathy of prematurity (ROP) in infants. ROP is a significant cause of blindness in children, and current treatments like laser or cryotherapy often yield poor visual outcomes. By inhibiting vascular endothelial growth factor (VEGF), the study aims to prevent harmful neovascularization associated with advanced stages of ROP. The trial focuses on infants with ROP stages III, IV, and V who cannot be treated with traditional methods.
Who should consider this trial
Good fit: Ideal candidates are infants diagnosed with stages III, IV, or V retinopathy of prematurity who are not eligible for laser or cryotherapy treatments.
Not a fit: Patients who can be treated effectively with cryotherapy or laser therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve visual outcomes and reduce blindness in infants with advanced ROP.
How similar studies have performed: Other studies have shown promising results with antiangiogenic therapies in similar conditions, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY Exclusion Criteria: * PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER
Where this trial is running
Mexico City, Mexico DF
- Asociación para Evitar la Ceguera en México Hospital "Luis Sanchez Bulnes" — Mexico City, Mexico DF, Mexico (Recruiting)
Study contacts
- Principal investigator: Maria Martínez-Castellanos, MD — Asociación para Evitar la Ceguera en México
- Study coordinator: Hugo Quiroz-Mercado, MD
- Email: retinamex@yahoo.com
- Phone: 525510841400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.